Full-Length SMN Transcript in Extracellular Vesicles as Biomarker in Individuals with Spinal Muscular Atrophy Type 2 Treated with Nusinersen

被引:6
|
作者
Trifunov, Selena [1 ,6 ]
Natera-de Benito, Daniel [1 ,2 ]
Carrera-Garcia, Laura [1 ,2 ]
Codina, Anna [1 ]
Exposito-Escudero, Jesica [1 ,2 ]
Ortez, Carlos [1 ]
Medina, Julita [4 ]
Torres Alcala, Soraya [3 ]
Bernal, Sara [5 ,6 ]
Alias, Laura [5 ,6 ]
Badosa, Carmen [1 ]
Balsells, Sol [7 ]
Alcolea, Daniel [3 ]
Nascimento, Andres [1 ,2 ,6 ]
Jimenez-Mallebrera, Cecilia [1 ,6 ,8 ]
机构
[1] Inst Recerca St Joan De Deu, Appl Res Neuromuscular Dis, Barcelona, Spain
[2] Hosp San Juan Dios, Dept Neurol, Neuromuscular Unit, Barcelona, Spain
[3] Univ Autonoma Barcelona, Inst Invest Biomed St Pau Hosp St Pau, Hosp Santa Creu & St Pau, Dept Neurol, Barcelona, Spain
[4] Hosp St Joan De Deu, Rehabil & Phys Unit Dept, Barcelona, Spain
[5] Univ Autonoma Barcelona, Inst Invest Biomed St Pau Hosp St Pau, Dept Genet, Barcelona, Spain
[6] Inst Salud Carlos III, Biomed Network Res Ctr Rare Dis CIBERER, Madrid, Spain
[7] Inst Recerca St Joan De Deu, Stat Dept, Barcelona, Spain
[8] Univ Barcelona, Dept Genet Microbiol & Stat, Barcelona, Spain
关键词
Biomarkers; cerebrospinal fluid; nusinersen; response predictors; serum; spinal muscular atrophy; SHAM CONTROL; EXPRESSION; EXOSOMES;
D O I
10.3233/JND-230012
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Three therapeutic strategies have radically changed the therapeutic scenario for spinal muscular atrophy (SMA). However, therapeutic response differs between individuals. There is a need to identify biomarkers to further assess therapeutic response and to better understand which variables determine the extent of response. Methods: We conducted a study using an optimized digital droplet PCR-based method for the ultra-sensitive detection of SMN transcript in serum EVs from SMA 2 individuals treated with nusinersen over 14 months. In parallel, we investigated levels of serum and CSF neurofilament heavy chain (pNF-H) in the same cohort. Results: Expression of flSMN transcript in EVs of SMA 2 individuals prior to nusinersen was lower than in controls (0.40 vs 2.79 copies/ul; p < 0.05) and increased after 14 months of nusinersen (0.40 vs 1.11 copies/ul; p < 0.05). The increase in flSMN with nusinersen was significantly higher in younger individuals (p < 0.05). Serum pNF-h was higher in non-treated individuals with SMA 2 than in controls (230.72 vs 22.88 pg/ml; p < 0.05) and decreased with nusinersen (45.72 pg/ml at 6 months, 39.02 pg/ml at 14 months). CSF pNF-h in SMA 2 individuals also decreased with nusinersen (248.04 pg/ml prior to treatment, 197.10 pg/dl at 2 months, 104.43 pg/dl at 6 months, 131.03 pg/dl at 14 months). Conclusions: We identified an increase of flSMN transcript in serum EVs of SMA 2 individuals treated with nusinersen that was more pronounced in the younger individuals. Our results indicate that flSMN transcript expression in serum EVs is a possible biomarker in SMA to predict or monitor the response to treatment.
引用
收藏
页码:653 / 665
页数:13
相关论文
共 50 条
  • [11] Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen
    Ergenekon, Almala Pinar
    Yegit, Cansu Yilmaz
    Cenk, Muruvvet
    Gokdemir, Yasemin
    Eralp, Ela Erdem
    Ozturk, Gulten
    Unver, Olcay
    Coskun, Ozge Kenis
    Saygi, Evrim Karadag
    Turkdogan, Dilsad
    Karadag, Bulent
    PEDIATRICS INTERNATIONAL, 2022, 64 (01)
  • [12] Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen
    Sansone, Valeria A.
    Pirola, Alice
    Albamonte, Emilio
    Pane, Marika
    Lizio, Andrea
    D'Amico, Adele
    Catteruccia, Michela
    Cutrera, Renato
    Bruno, Claudio
    Pedemonte, Marina
    Messina, Sonia
    Rao, Fabrizio
    Roma, Elisabetta
    Salmin, Francesca
    Coratti, Giorgia
    Di Bari, Alessandra
    De Sanctis, Roberto
    Pera, Carmela Maria
    Sframeli, Maria
    Piastra, Marco
    Macagno, Francesco
    Vita, Giuseppe
    Bertini, Enrico
    Mercuri, Eugenio
    JOURNAL OF PEDIATRICS, 2020, 219 : 223 - +
  • [13] Respiratory management of spinal muscular atrophy type 1 patients treated with Nusinersen
    Menard, Joris
    Seferian, Andreea M.
    Fleurence, Emmanuelle
    Barzic, Audrey
    Binoche, Alexandra
    Labouret, Geraldine
    Coutier, Laurianne
    Vuillerot, Carole
    Bieleu, Blaise M.
    de la Banda, Marta Gomez Garcia
    Corvol, Harriet
    Servais, Laurent
    Taytard, Jessica
    PEDIATRIC PULMONOLOGY, 2022, 57 (06) : 1505 - 1512
  • [14] Clinical Outcomes in Patients with Spinal Muscular Atrophy Type 1 Treated with Nusinersen
    Mendonca, Rodrigo de Holanda
    Polido, Graziela Jorge
    Matsui, Ciro, Jr.
    Fontoura Solla, Davi Jorge
    Reed, Umbertina Conti
    Zanoteli, Edmar
    JOURNAL OF NEUROMUSCULAR DISEASES, 2021, 8 (02) : 217 - 224
  • [15] Nusinersen Experience in Individuals with Spinal Muscular Atrophy (SMA) Type III: A Case Series
    Chiriboga, C.
    Kirschner, J.
    Swoboda, K.
    Mercuri, E.
    Darras, B.
    Foster, R.
    Bhan, I
    Farwell, W.
    ANNALS OF NEUROLOGY, 2018, 84 : S351 - S351
  • [16] Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy
    Schorling, David C.
    Koelbel, Heike
    Hentschel, Andreas
    Pechmann, Astrid
    Meyer, Nancy
    Wirth, Brunhilde
    Rombo, Roman
    Sickmann, Albert
    Kirschner, Janbernd
    Schara-Schmidt, Ulrike
    Lochmuller, Hanns
    Roos, Andreas
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (07) : 2084 - 2096
  • [17] Nusinersen improved respiratory function in spinal muscular atrophy type 2
    Tanaka, Ryuta
    Fukushima, Fujiko
    Motoyama, Keiichi
    Kobayashi, Chie
    Izumi, Isho
    PEDIATRICS INTERNATIONAL, 2021, 63 (08) : 973 - 974
  • [18] Language development in spinal muscular atrophy (SMA) type 1 children treated with nusinersen
    Brusa, C.
    Scoto, M.
    Manzur, A.
    Main, M.
    Muntoni, F.
    Vargha-Khadem, F.
    Baranello, G.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S187 - S187
  • [19] Nonrespiratory complications of nusinersen-treated spinal muscular atrophy type 1 patients
    Lavie, Moran
    Rochman, Mika
    Sagi, Liora
    Feler, Anat Yerushalmy
    Ovadia, Dror
    Cahal, Michal
    Be'er, Moria
    Sadot, Efraim
    Fattal-Valevski, Aviva
    Amirav, Israel
    PEDIATRIC PULMONOLOGY, 2022, 57 (03) : 686 - 694
  • [20] Clinical and Electropthysiological outcomes of Spinal Muscular Atrophy type 1 patients treated with Nusinersen
    Kern-Smith, Emily
    Verma, Sumit
    NEUROLOGY, 2019, 92 (15)